Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Oral Semaglutide

OASIS 2

Novo Nordisk · Phase 3 · Completed · Enrollment 201

NCT05132088

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
oral semaglutide 50 mg once dailyn/rn/rn/rn/r
oral semaglutide placebo once dailyn/rn/rn/rn/r

Not shown

  • oral semaglutide 50 mg once daily: endpoint not reported
  • oral semaglutide placebo once daily: endpoint not reported